| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Jul'12 | Jul'11 |
|---|---|---|---|---|---|---|---|---|
Product revenue | ||||||||
- | - | - | - | - | 0 | 0 | - | - |
Technical development fees | ||||||||
- | - | - | - | - | - | - | - | -842 |
Licensing and royalty revenues | ||||||||
- | - | - | - | - | 122 | 48 | 236 | 34 |
Net sales | ||||||||
9,297 | 5,670 | 4,177 | 246 | 147 | 122 | 48 | 236 | 1,121 |
License fees | ||||||||
- | - | - | - | - | - | - | - | 0 |
Qualified discovery therapeutic grant | ||||||||
- | - | - | - | - | - | - | - | 244 |
Cost of sales | ||||||||
4,897 | 3,187 | 1,002 | 0 | 0 | - | - | - | - |
Gross profit | ||||||||
4,400 | 2,483 | 3,175 | 246 | 147 | - | - | - | - |
Costs and expenses: | ||||||||
Research and development | ||||||||
25,345 | 27,638 | 22,301 | 29,564 | 27,142 | 19,526 | 10,673 | 432 | 454 |
Sales, general and administrative | ||||||||
51,886 | 55,214 | 45,058 | 37,183 | 18,554 | 10,695 | 4,312 | 2,954 | 819 |
Amortization | ||||||||
- | - | - | - | - | 71 | 77 | 203 | 253 |
Depreciation | ||||||||
- | - | - | - | - | 817 | 286 | 2 | 2 |
Impairment of intangibles | ||||||||
- | - | - | - | - | 3 | 11 | 1,997 | 0 |
Total costs and expenses | ||||||||
77,231 | 82,852 | 67,359 | 66,747 | 45,696 | 31,112 | 15,359 | 5,588 | 1,530 |
Loss from operations | ||||||||
-72,831 | -80,369 | -64,184 | -66,501 | -45,549 | -30,990 | -15,311 | -5,352 | -409 |
Other income (expense): | ||||||||
Interest expense | ||||||||
-14,256 | -10,113 | 0 | 0 | -4 | - | - | - | - |
Foreign currency exchange loss | ||||||||
-124 | -450 | -75 | -77 | -19 | 0 | - | - | - |
Interest income | ||||||||
2,809 | 2,845 | 908 | 494 | 74 | 64 | 29 | 16 | - |
Interest expense | ||||||||
- | - | - | - | 0 | 7 | 0 | 1 | 0 |
Unrealized holding (loss) gain on investments | ||||||||
- | - | - | - | - | - | - | 24 | 14 |
Other income, net | ||||||||
- | - | - | - | 51 | 57 | 29 | 41 | 16 |
Other expense, net | ||||||||
14 | 28 | 184 | 23 | - | - | - | - | - |
Total other expense, net | ||||||||
-11,585 | -7,746 | 649 | 394 | - | - | - | - | - |
Net loss before income taxes | ||||||||
-84,416 | -88,115 | -63,535 | -66,107 | -45,498 | -30,933 | -15,282 | - | 30 |
Unrealized holding gain on asset sale | ||||||||
- | - | - | - | - | - | - | - | 0 |
Net loss before income taxes | ||||||||
- | - | - | - | - | - | - | -5,311 | - |
Provision for income taxes | ||||||||
-111 | 211 | 493 | 267 | 0 | 0 | - | - | - |
Net loss | ||||||||
-84,305 | -88,326 | -64,028 | -66,374 | -45,498 | -30,933 | -15,282 | -5,311 | -378 |
Basic and diluted net loss per share (usd per share) | ||||||||
-1.55 | -1.62 | -1.18 | -1.29 | -1.01 | -0.71 | -0.41 | -0.43 | -0.04 |
Weighted average shares outstanding (shares) | ||||||||
54,506 | 54,494 | 54,073 | 51,276 | 44,998 | 43,626 | 37,599 | 12,462 | 10,791 |
Other comprehensive loss: | ||||||||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ||||||||
- | - | - | - | - | - | -15,282 | - | - |
Other comprehensive loss: | ||||||||
Net loss | ||||||||
-84,305 | -88,326 | -64,028 | -66,374 | -45,498 | -30,933 | -15,282 | -5,311 | -378 |
Net unrealized gain on debt securities available-for-sale | ||||||||
193 | 23 | -117 | -64 | -20 | -15 | 22 | - | 0 |
Foreign currency translation adjustment | ||||||||
-102 | -172 | 321 | -128 | 1 | 0 | 0 | - | - |
Comprehensive loss | ||||||||
-84,214 | -88,475 | -63,824 | -66,566 | -45,517 | -30,948 | -15,260 | -5,311 | -378 |